Abilify gains US approval for adjunctive maintenance use in bipolar disorder
This article was originally published in Scrip
Otsuka Pharmaceutical/Bristol-Myers Squibb's atypical antipsychotic Abilify (aripiprazole) has been approved in the US for the maintenance treatment of bipolar I disorder in conjunction with either lithium or valproate therapy.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context